EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Update on the diagnosis and management of cystic fibrosis pulmonary exacerbations

Jonathan D Cogen, Bradley S Quon

Journal of Cystic Fibrosis · 2024-07 · 23 (4) · 603-611

DOI: 10.1016/j.jcf.2024.04.004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Cystic Fibrosis, 2024-07. Verfasst von Jonathan D Cogen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Sleep Medicine, Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, Washington, USA. …. Hauptthemen laut MEDLINE: Cystic Fibrosis, Disease Progression. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cystic Fibrosis Foundation, Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pulmonary exacerbations in people with cystic fibrosis are associated with significant morbidity and reduced quality of life. Pulmonary exacerbation treatment guidelines, published by an expert panel assembled by the Cystic Fibrosis Foundation nearly 15 years ago, were primarily consensus-based as there were several gaps in the evidence base. In particular, limited evidence existed regarding optimal pulmonary exacerbation treatment strategies, including duration of antibiotic therapy, treatment location, antibiotic selection, and the role of systemic corticosteroids. Over the last decade, results from observational studies and large multi-center randomized controlled trials have begun to answer important questions related to pulmonary exacerbation treatment. This review focuses on the diagnosis, etiology, and changing epidemiology of pulmonary exacerbations, and also summarizes the most recent and up-to-date studies describing pulmonary exacerbation treatment. Finally, this review provides consideration for future pulmonary exacerbation research priorities, particularly in the current highly effective modulator therapy era.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisDisease ProgressionHumansAnti-Bacterial AgentsDisease Management

Stichwörter der Autor:innen

AntibioticsCystic fibrosisDiagnosisPulmonary exacerbationsTreatment

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Division of Pulmonary and Sleep Medicine, Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, Washington, USA. Electronic address: jonathan.cogen@seattlechildrens.org.
  • Division of Respiratory Medicine, Department of Medicine, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.

Förderung

  • Cystic Fibrosis Foundation
  • Gilead Sciences

Zitieren

APA

Cogen, J. D., & Quon, B. S. (2024). Update on the diagnosis and management of cystic fibrosis pulmonary exacerbations. Journal of Cystic Fibrosis, 23(4), 603-611. https://doi.org/10.1016/j.jcf.2024.04.004

Vancouver

Cogen JD, Quon BS. Update on the diagnosis and management of cystic fibrosis pulmonary exacerbations. Journal of Cystic Fibrosis. 2024;23(4):603-611. doi:10.1016/j.jcf.2024.04.004

BibTeX
@article{Cogen2024,
  author = {Cogen, Jonathan D and Quon, Bradley S},
  title = {Update on the diagnosis and management of cystic fibrosis pulmonary exacerbations},
  journal = {Journal of Cystic Fibrosis},
  year = {2024},
  volume = {23},
  number = {4},
  pages = {603--611},
  doi = {10.1016/j.jcf.2024.04.004}
}
Kostenlos starten →